8-Chloro-dibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid 2-[1-oxo-3-(4-pyridinyl)propyl]hydrazide monohydrochloride

SC-51089 is a selective antagonist of prostaglandin E2, which displays specificity towards the EP1 receptor subtype. Studies indicate that SC-51089 can induce nociceptive behaviors in rats as a result of its antagonistic effects on prostaglandin E2. This compound contains a diacylhydrazine moiety, which has often been observed to release hydrazine. Alternate studies suggest that SC-51089 can be metabolized by rat and human hepatocytes, however different metabolic products are produced. For instance, SC-51089 undergoes aromatic hydroxylation with consequent glucuronidation and sulphation in human hepatocytes, while oxidative N-dealkylation with opening of the oxazepine ring and consequent glucuronidation in observed in rat hepatocytes. SC-51089 is an inhibitor of EP2 and EP3.